# of Displayed Technologies: 13 / 13

Applied Category Filter (Click To Remove): Oncology


Categories

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: Ezzell, Janel

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Bartell, Cordellia

Self-assembled 3D RNA Cage Nanoparticles with Precise Shape and Size for Applications in Medical Sciences, Materials Sciences, Engineering and Nanotechnology
TS-039545 — Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery
One of the primary challenges in therapeutic development is cheap, efficient, and safe drug delivery to specific target tissues. To better target specific tissues, RNA nanotechnology has been progressively applied to generate predefined architectures via self-assembly of modular building blocks. N…
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel; Khisamutdinov, Emil; Li, Hui; Xu, Congcong
  • Licensing Officer: Ezzell, Janel

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Ezzell, Janel

Cancer Cell Motility Monitoring Device
TS-038384 — A novel device for monitoring cancer cell motility in real time using standard microscopy.
The Need Numerous cancer cells are capable of migration, resulting in metastasis of distinct organs and tissues from where the cancer first arose. Migrating cancer cells are known to directionally respond to applied electric fields, a phenomenon called electrotaxis, as well as topological cues prov…
  • College: College of Engineering (COE)
  • Inventors: Garg, Ayush; Bushman, Sarah; Ferree, Jessica; Jones, Travis; Song, Jonathan; Subramaniam, Vishwanath
  • Licensing Officer: Zinn, Ryan

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Ezzell, Janel

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Ezzell, Janel

Development of STAT3 dimerization inhibitors for cancers
TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
  • Licensing Officer: Ezzell, Janel

Targeting EGFL7 in AML
TS-037353 — Treatment of blood cancer with anti-EGFL7 antibody.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival is only 30-40% in younger (<60 years) and <10% in older adult AML patients. This highlights the urgent need for novel therapeutic approaches for a…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Ezzell, Janel

Immunomodulating agents engineered from Notch receptor ligand extracellular domains
TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Carbone, David; Dikov, Mikhail; Long, Nicholas; Sullivan, Brandon; Tchekneva, Elena
  • Licensing Officer: Davis, Stewart

Self-Assembly of Therapeutic-Agent Nanostructures
TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Bartell, Cordellia

Loading icon